Key Stats for Regeneron Pharmaceuticals Stock
- Past-Week Performance: +0.2%
- 52-Week Range: $476.5 to $821.1
- Current Price: $766.7
What Happened?
Regeneron stock (REGN) at $766.66 reflects a company executing on multiple simultaneous regulatory wins while its core DUPIXENT franchise grows to $17.8 billion annually across 1.4 million patients globally.
The FDA approved Dupixent on February 24 for allergic fungal rhinosinusitis in patients aged 6 and older, making it the first approved treatment for the condition and pushing its U.S. approved indications to nine.
That ninth indication compounds a franchise already generating $4.9 billion in a single quarter, with Regeneron’s share of Sanofi collaboration profits surging 42% year-over-year in Q4.
Leonard Schleifer, President and CEO, stated on the Q4 earnings call that “we anticipate at least 4 FDA approvals, including 3 for new molecular entities across 3 distinct modalities,” with the garetosmab BLA already accepted by the FDA on February 19 under Priority Review targeting an August decision.
With the EMA’s CHMP backing Dupixent’s expansion into children aged 2 to 11 for chronic spontaneous urticaria on February 27, an April FDA decision pending for the same indication, and Lynozyfic achieving MRD negativity in all nine evaluable newly diagnosed myeloma patients, Regeneron is building a multi-franchise platform that extends its pricing power and competitive moat well into the next decade.
Wall Street’s Take on REGN Stock
Dupixent’s ninth FDA approval on February 24 for allergic fungal rhinosinusitis directly expands the addressable patient pool driving the $17.8 billion franchise, reinforcing consensus forecasts for 9.0% revenue growth in 2026.
Analysts project revenue climbing from $14.3 billion in 2025 to $15.6 billion in 2026, while normalized EPS stabilizes at $44.7 after a 2.9% decline, signaling a business finding its earnings floor before re-acceleration.
Wall Street currently fields 17 buys, 2 outperforms, 8 holds, and 1 underperform, with a mean price target of $870.7 representing 13.6% upside from the March 3 close of $766.7, reflecting conviction held through a prolonged pullback from the 52-week high.
The analyst target range spans $730.0 on the low end to $1,057.0 on the high end, with the upside scenario hinging directly on fianlimab’s first-line melanoma readout expected in the first half of 2026 and the August garetosmab FDA decision.
What Does the Valuation Model Say?
The TIKR valuation model targets $1,226.8 by December 31, 2030, implying 60.0% total return and a 10.2% IRR annually against a stock trading at $766.7 today.
The market prices REGN as a maturing drug company, yet its pipeline carries four expected 2026 FDA approvals across three distinct modalities simultaneously.
Normalized net income margins held at 34.1% in 2025 despite an 8.1% earnings decline, demonstrating structural profitability that the current multiple does not adequately reward.
Management’s commitment of $5.9 billion to $6.1 billion in 2026 R&D, paired with 18 new Phase 3 initiations, signals that leadership sees a pipeline worth funding aggressively, not a company in harvest mode.
Multiple EYLEA 2mg biosimilar launches expected in the second half of 2026 could accelerate revenue erosion in the retinal franchise, directly pressuring the 83% to 84% gross margin guidance.
The fianlimab pivotal readout in first-line metastatic melanoma, expected in the first half of 2026, will determine whether Regeneron can establish a second oncology blockbuster alongside LIBTAYO.
REGN trades at a steep discount to its model-implied fair value of $1,226.8, and the fianlimab readout is the catalyst that could force a rerating.
Should You Invest in Regeneron Pharmaceuticals, Inc.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up REGN stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Regeneron Pharmaceuticals, Inc. alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze REGN stock on TIKR for Free →
